Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more
Jeil Pharm (002620) - Net Assets
Latest net assets as of September 2025: ₩460.63 Billion KRW
Based on the latest financial reports, Jeil Pharm (002620) has net assets worth ₩460.63 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩860.96 Billion) and total liabilities (₩400.33 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩460.63 Billion |
| % of Total Assets | 53.5% |
| Annual Growth Rate | 5.02% |
| 5-Year Change | -12.4% |
| 10-Year Change | 81.2% |
| Growth Volatility | 73.08 |
Jeil Pharm - Net Assets Trend (2011–2024)
This chart illustrates how Jeil Pharm's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jeil Pharm (2011–2024)
The table below shows the annual net assets of Jeil Pharm from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩437.40 Billion | +8.75% |
| 2023-12-31 | ₩402.19 Billion | -4.19% |
| 2022-12-31 | ₩419.79 Billion | -16.09% |
| 2021-12-31 | ₩500.31 Billion | +0.21% |
| 2020-12-31 | ₩499.28 Billion | +3.36% |
| 2019-12-31 | ₩483.04 Billion | -18.07% |
| 2018-12-31 | ₩589.58 Billion | +245.92% |
| 2017-12-31 | ₩170.44 Billion | -32.39% |
| 2016-12-31 | ₩252.08 Billion | +4.43% |
| 2015-12-31 | ₩241.39 Billion | -0.01% |
| 2012-12-31 | ₩241.41 Billion | +4.33% |
| 2011-12-31 | ₩231.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jeil Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 87.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩26.15 Billion | 8.52% |
| Other Components | ₩280.80 Billion | 91.48% |
| Total Equity | ₩306.95 Billion | 100.00% |
Jeil Pharm Competitors by Market Cap
The table below lists competitors of Jeil Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Donegal Investment Group PLC
IR:DQ7A
|
$13.28 Million |
|
Foresta Group Holdings Ltd
AU:FGH
|
$13.28 Million |
|
Carriesoft Co. Ltd
KQ:317530
|
$13.28 Million |
|
Puriblood Medical Co., Ltd.
TWO:6847
|
$13.28 Million |
|
US Energy Corp
NASDAQ:USEG
|
$13.28 Million |
|
Senheng New Retail Bhd
KLSE:5305
|
$13.28 Million |
|
The Market Ltd
AU:MKT
|
$13.27 Million |
|
Asefa Public Company Limited
BK:ASEFA
|
$13.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jeil Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 319,461,150,930 to 306,949,796,440, a change of -12,511,354,490 (-3.9%).
- Net loss of 51,159,360,660 reduced equity.
- Dividend payments of 1,133,875,340 reduced retained earnings.
- Other factors increased equity by 39,781,881,510.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-51.16 Billion | -16.67% |
| Dividends Paid | ₩1.13 Billion | -0.37% |
| Other Changes | ₩39.78 Billion | +12.96% |
| Total Change | ₩- | -3.92% |
Book Value vs Market Value Analysis
This analysis compares Jeil Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.20x to 0.45x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩44781.97 | ₩8970.00 | x |
| 2018-12-31 | ₩31941.23 | ₩8970.00 | x |
| 2019-12-31 | ₩25632.11 | ₩8970.00 | x |
| 2020-12-31 | ₩26542.15 | ₩8970.00 | x |
| 2021-12-31 | ₩26820.87 | ₩8970.00 | x |
| 2022-12-31 | ₩22002.60 | ₩8970.00 | x |
| 2023-12-31 | ₩20810.28 | ₩8970.00 | x |
| 2024-12-31 | ₩19995.26 | ₩8970.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jeil Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.56%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 2.90x
- Recent ROE (-16.67%) is below the historical average (22.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 11.67% | 5.84% | 1.20x | 1.66x | ₩3.88 Billion |
| 2012 | 4.63% | 2.62% | 1.09x | 1.62x | ₩-12.97 Billion |
| 2015 | 4.04% | 1.64% | 1.34x | 1.84x | ₩-14.38 Billion |
| 2016 | 3.17% | 1.28% | 1.25x | 1.98x | ₩-17.00 Billion |
| 2017 | 311.16% | 1167.44% | 0.22x | 1.19x | ₩502.14 Billion |
| 2018 | 1.44% | 4.95% | 0.16x | 1.88x | ₩-41.96 Billion |
| 2019 | -23.04% | -12.50% | 0.86x | 2.15x | ₩-130.01 Billion |
| 2020 | 2.81% | 1.50% | 0.86x | 2.18x | ₩-29.31 Billion |
| 2021 | -0.85% | -0.46% | 0.85x | 2.17x | ₩-44.66 Billion |
| 2022 | -22.07% | -9.40% | 0.92x | 2.56x | ₩-108.33 Billion |
| 2023 | -5.09% | -2.02% | 0.91x | 2.75x | ₩-48.20 Billion |
| 2024 | -16.67% | -6.56% | 0.88x | 2.90x | ₩-81.85 Billion |
Industry Comparison
This section compares Jeil Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jeil Pharm (002620) | ₩460.63 Billion | 11.67% | 0.87x | $13.28 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |